Data / Form D filings / Immunovant, Inc.
Immunovant, Inc.: Form D filing
Immunovant, Inc., a pharmaceuticals company in New York, NY, filed a Form D with the SEC in 2025. The latest, on January 21, 2025, reports $450 million sold of a $450 million offering to 11 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 320 WEST 37TH STREET, New York, NY, 10018
- Phone
- (917) 580-3099
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1764013
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 21, 2025 | New notice | $450,000,000 | $450,000,000 | 11 | Jan 15, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christopher Van Tuyl | Executive Officer | |
| Michael Geffner | Executive Officer | |
| Andrew Fromkin | Director | |
| Atul Pande | Director | |
| George Migausky | Director | |
| Eric Venker | Director | |
| Frank Torti | Director | |
| Pete Salzmann | Executive Officer, Director | |
| Jay Stout | Executive Officer | |
| Melanie Gloria | Executive Officer | |
| Eva Renee Barnett | Executive Officer | |
| Bill Macias | Executive Officer | |
| Douglas Hughes | Director |
Other pharmaceuticals companies in New York that filed recently
- Pierrepont Therapeutics, Inc. $2.4 million · Sep 22, 2026
Every Form D from the week of Jan 20, 2025 · All recent filings in New York · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Immunovant, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.